Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas

Trial Title: Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas

NCT ID: NCT05515068

Condition: Osteosarcoma
Bone Tumor
Bone Sarcoma
High Grade Sarcoma
Osteoblastic Osteosarcoma
Chondroblastic Osteosarcoma
Fibroblastic Osteosarcoma
Conventional Osteosarcoma
Conventional Central Osteosarcoma of Bone
Low Grade Central Osteosarcoma
Osseous Sarcoma
Osseous Tumor
Small Cell Osteosarcoma
Telangiectatic Osteosarcoma
Undifferentiated Pleomorphic Sarcoma
Parosteal Osteosarcoma
Periosteal Osteosarcoma
Extraskeletal Osteosarcoma
Recurrent Osteosarcoma
High Grade Surface Osteosarcoma
Osseous Angiosarcoma
Osseous Fibrosarcoma
Osseous Leiomyosarcoma
Osseous Dedifferentiated Chondrosarcoma
Osseous Mesenchymal Chondrosarcoma
Clear Cell Osteosarcoma

Conditions: Official terms:
Sarcoma
Osteosarcoma
Leiomyosarcoma
Chondrosarcoma
Hemangiosarcoma
Fibrosarcoma
Histiocytoma, Malignant Fibrous
Chondrosarcoma, Mesenchymal
Osteosarcoma, Juxtacortical

Study type: Observational [Patient Registry]

Overall status: Not yet recruiting

Study design:

Time perspective: Prospective

Summary: The Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry) is a non-interventional, multicentric, international, clinical and epidemiologic patient registry. The COSS-Registry collects key data on osteosarcomas or biologically related bone sarcomas. With that data collection we want to gain new scientific insights and results about this tumor disease, prognosis, surveillance and long-term effects. Besides the data collection we would also like to foster the collection of biomaterial (tumor specimen and blood samples) for scientific research. The stored material will be used to perform cell and molecular biological analyses to identify the causes of osteosarcoma, the prognosis and possible new treatment options. As a starting point the donated biomaterial of registered patients will be analyzed firstly for the presence of a tumor predisposition by germline mutations. In case of detected genetic variations that are related to the tumor disease and which may affect the patient's health and follow-up care (because of the potentially increased risk of developing other malignant tumors), affected patients will be informed and referred to genetic counseling. Registry patients will be asked at the time of diagnosis if they wish to be informed about germline variants detected as part of the study procedures.

Detailed description: Osteosarcomas are rare and malignant bone tumors with an incidence of only 200-300 diagnoses in Germany each year. The biological behaviour of the tumor is not well understood yet. Treatment options and survival prognosis have not improved for the last decades. The planned collection of treatment and follow-up data of affected patients at the COSS-Registry has the goal to gain further insights about this tumor, to improve survival rates and to identify possible germline variants in tumor predisposition genes in any patient diagnosed with OS. It is also necessary to foster research on the genetic and molecular biological characteristics of osteosarcoma by analyzing biomaterial samples (especially tumor tissue) for example to identify new therapy targets or to evaluate the response to and the adverse effects of chemotherapy with respect to the germline alterations. Therefore a substantial amount of biomaterial has to be gathered and stored in a biobank. Accompanying to the COSS-Registry's data collection, biological samples taken from registered patients during routine measures and which are no longer required for further treatment will be stored in the COSS-Biobank. The biological samples collected will be used to carry out genetic tests to check for an underlying tumor predisposition by germline mutations and for a next-generation sequencing of the whole genome. The goal of this project is to prospectively characterize the germline genetics in OS patients, to increase the understanding of the impact of germline alterations on the age of manifestation of OS, to evaluate the response to and the adverse effects of chemotherapy with respect to the germline alterations and to integrate germline investigation and counselling into the routine workup of any child, adolescent or young adult diagnosed with OS registered at the COSS-Registry. In this way, affected patients will benefit from their participation in the COSS-Registry and COSS-Biobank.

Criteria for eligibility:

Study pop:
All patients irrespective of gender, age and tumour location

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - high-grade osteosarcoma (conventional and non-conventional) - parosteal, periosteal or extraosseous osteosarcoma - low grade central osteosarcoma - (osseous) Undifferentiated pleomorphic sarcoma (UPS) - (osseous) leiomyosarcoma - (osseous) dedifferentiated chondrosarcoma - (osseous) mesenchymal chondrosarcoma - (osseous) fibrosarcoma - (osseous) angiosarcoma - informed consent Exclusion Criteria: - no informed consent

Gender: All

Minimum age: N/A

Maximum age: N/A

Healthy volunteers: No

Start date: September 2022

Completion date: March 2032

Lead sponsor:
Agency: Klinikum Stuttgart
Agency class: Other

Collaborator:
Agency: Klinikum Kassel GmbH (COSS-Biobank)
Agency class: Other

Source: Klinikum Stuttgart

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05515068